Publications – Agios Pharmaceuticals, Inc.

Year

Dec 14, 2021

Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Survey of 275 Patients and Caregivers Affected By Pyruvate Kinase Deficiency: Impact of Communication with Hematologists on Mental Health and Quality of Life

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Safety and Efficacy of Mitapivat(AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Pharmacodynamic effects of AG 946, a highly potent next generation activator of pyruvate kinase, in ex vivo treatment of red blood cells from sickle cell disease patients

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Mitapivat Improves Transfusion Burden and Reduces Iron Overload in Thalassemic Mice

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Alpha-or Beta-Thalassemia

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase Deficiency

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Characterizing Iron Overload by Age in Patients Diagnosed with Pyruvate Kinase Deficiency – A Descriptive Analysis from the Peak Registry

Source

ASH 2021 Annual Meeting

Dec 14, 2021

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivatin Patients with Sickle Cell Disease

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Durability of Hemoglobin Response and Reduction in Transfusion Burden is Maintained Over Time in Patients With Pyruvate Kinase Deficiency Treated with Mitapivatin a Long-Term Extension Study

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Validation of the Pyruvate Kinase Deficiency Diary (PKDD): a patient-reported outcome measure for pyruvate kinase (PK) deficiency

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Validation of the Pyruvate Kinase Deficiency Impact Assessment (PKDIA): a patient-reported outcome measure for pyruvate kinase (PK) deficiency

Source

ASH 2021 Annual Meeting

Dec 14, 2021

Results from Phase 1 Multiple Ascending Dose Study of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Source

ASH 2021 Annual Meeting

Jun 11, 2021

ACTIVATE: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Of Mitapivat In Adults With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Source

EHA Congress 2021

Jun 11, 2021

ACTIVATE-T: A Phase 3, Open-label, Multicenter Study Of Mitapivat In Adults With Pyruvate Kinase Deficiency Who Are Regularly Transfused

Source

EHA Congress 2021

Jun 11, 2021

Bone Mineral Density Is Stable in Adults With Pyruvate Kinase Deficiency Receiving Long-Term Treatment With Mitapivat

Source

EHA Congress 2021

Jun 11, 2021

Early-Onset Osteopenia and Osteoporosis in Patients With Pyruvate Kinase Deficiency

Source

EHA Congress 2021

Jun 11, 2021

Baseline Characteristics by Age of a Global Cohort of Patients Diagnosed with Pyruvatekinase Deficiency – a Descriptive Analysis from the PEAK Registry

Source

EHA Congress 2021

Jun 11, 2021

Mortality Among Veterans With a Diagnosis of Pyruvate Kinase Deficiency: A Real-World Study Using US Veterans Health Administration Data

Source

EHA Congress 2021

Jun 11, 2021

The Lifetime Economic Burden of Pyruvate Kinase Deficiency in the United States

Source

EHA Congress 2021

Jun 11, 2021

Results From a Phase 2, Open-Label, Multicenter Study of the Oral Pyruvate Kinase Activator Mitapivat in Adults With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia

Source

EHA Congress 2021

Jun 11, 2021

Global Thalassemia Epidemiology: A Systematic Literature Review

Source

EHA Congress 2021

Jun 11, 2021

Mitapivat Ameliorates Red Cell Features and Decreases Anemia in Band 4.2-/- Mice, A Model of Hereditary Spherocytosis

Source

EHA Congress 2021

For details on our former oncology programs, visit https://www.servier.us/.